Molecular Cancer Research Infection and Cancer: Biology, Therapeutics, and Prevention Chemical and Biological Aspects of Inflammation and Cancer
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Slaton, J. W.
Right arrow Articles by Ahmed, K.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Slaton, J. W.
Right arrow Articles by Ahmed, K.
Molecular Cancer Research 2:712-721 (2004)
© 2004 American Association for Cancer Research


Signaling and Regulation

Induction of Apoptosis by Antisense CK2 in Human Prostate Cancer Xenograft Model1

Joel W. Slaton1,2,4, Gretchen M. Unger3, Daniel T. Sloper1, Alan T. Davis1 and Khalil Ahmed1,3,4

1 Minneapolis Veterans Affairs Medical Center, 2 Departments of Urologic Surgery and 3 Laboratory Medicine and Pathology, and 4 The Cancer Center, University of Minnesota, Minneapolis, Minnesota

Requests for reprints: Khalil Ahmed, Cellular and Molecular Biochemistry Research Laboratory (151), Veterans Affairs Medical Center, One Veterans Drive, Minneapolis, MN 55417. Phone: 612-467-2594; Fax: 612-725-2093. E-mail: ahmedk{at}umn.edu

Protein serine/threonine kinase CK2 (formerly casein kinase 2) is a ubiquitous protein kinase that plays key roles in cell growth, proliferation, and survival. We have shown previously that its molecular down-regulation induces apoptosis in cancer cells in culture. Here, we have employed a xenograft model of prostate cancer to extend these studies to determine whether antisense CK2{alpha} evokes a similar response in vivo. A single dose of antisense CK2{alpha} oligodeoxynucleotide given directly into the PC3-LN4 xenograft tumor in nude mouse induced a dose- and time-dependent tumor cell death in vivo. The tumor was completely resolved at the higher tested dose of the antisense. Cell death was due to apoptosis and correlated with a potent down-regulation of the CK2{alpha} message and loss of CK2 from the nuclear matrix in the xenograft tissue as well as in cancer cells in culture. These observations accorded with several of the earlier studies indicating that loss of CK2 from the nuclear matrix is associated with induction of apoptosis. Comparison of the effects of antisense CK2{alpha} oligodeoxynucleotide on cancer versus normal or noncancer cells showed that the concentration of antisense CK2{alpha} that elicited extensive apoptosis in tumor cells in culture or xenograft tumors in vivo had a relatively small or minimal effect on noncancer cells in culture or on normal prostate gland subjected to orthotopic injection of antisense oligodeoxynucleotide in vivo. The basis for the difference in sensitivity of cancer versus noncancer cells to antisense CK2{alpha} is unknown at this time; however, this differential response under similar conditions of treatment may be significant in considering the potential feasibility of targeting the CK2 signal for induction of apoptosis in cancer cells in vivo. Although much further work will be needed to establish the feasibility of targeting CK2 for cancer therapy, to our knowledge, this is the first report to provide important new evidence as an initial "proof of principle" for the potential application of antisense CK2{alpha} in cancer therapy, paving the way for future detailed studies of approaches to targeting CK2 in vivo to induce cancer cell death.

Key Words: antisense CK2 • prostate cancer • xenograft model • cell death • apoptosis




This article has been cited by other articles:


Home page
Cancer Res.Home page
L. Wang, D. T. Sloper, S. N. Addo, D. Tian, J. W. Slaton, and C. Xing
WL-276, an Antagonist against Bcl-2 Proteins, Overcomes Drug Resistance and Suppresses Prostate Tumor Growth
Cancer Res., June 1, 2008; 68(11): 4377 - 4383.
[Abstract] [Full Text] [PDF]


Home page
Molecular Cancer TherapeuticsHome page
K. A. Ahmad, N. H. Harris, A. D. Johnson, H. C.N. Lindvall, G. Wang, and K. Ahmed
Protein kinase CK2 modulates apoptosis induced by resveratrol and epigallocatechin-3-gallate in prostate cancer cells
Mol. Cancer Ther., March 1, 2007; 6(3): 1006 - 1012.
[Abstract] [Full Text] [PDF]


Home page
Mol Cancer ResHome page
K. A. Ahmad, G. Wang, and K. Ahmed
Intracellular Hydrogen Peroxide Production Is an Upstream Event in Apoptosis Induced by Down-Regulation of Casein Kinase 2 in Prostate Cancer Cells
Mol. Cancer Res., May 1, 2006; 4(5): 331 - 338.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
G. Wang, K. A. Ahmad, and K. Ahmed
Role of Protein Kinase CK2 in the Regulation of Tumor Necrosis Factor-Related Apoptosis Inducing Ligand-Induced Apoptosis in Prostate Cancer Cells
Cancer Res., February 15, 2006; 66(4): 2242 - 2249.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
K. Yamane and T. J. Kinsella
CK2 Inhibits Apoptosis and Changes Its Cellular Localization Following Ionizing Radiation
Cancer Res., May 15, 2005; 65(10): 4362 - 4367.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
Copyright © 2004 by the American Association for Cancer Research.